Literature DB >> 33354769

Reducing the rate of psychiatric re-admissions in bipolar disorder using smartphones-The RADMIS trial.

Maria Faurholt-Jepsen1, Morten Lindbjerg Tønning1, Mads Fros2, Klaus Martiny1, Nanna Tuxen1, Nicole Rosenberg1, Jonas Busk3, Ole Winther3,4,5, Daniel Thaysen-Petersen6, Kate Andreasson Aamund7, Lizzie Tolderlund7, Jakob Eyvind Bardram2,8, Lars Vedel Kessing1.   

Abstract

OBJECTIVES: The MONARCA I and II trials were negative but suggested that smartphone-based monitoring may increase quality of life and reduce perceived stress in bipolar disorder (BD). The present trial was the first to investigate the effect of smartphone-based monitoring on the rate and duration of readmissions in BD.
METHODS: This was a randomized controlled single-blind parallel-group trial. Patients with BD (ICD-10) discharged from hospitalization in the Mental Health Services, Capital Region of Denmark were randomized 1:1 to daily smartphone-based monitoring including a feedback loop (+ standard treatment) or to standard treatment for 6 months. Primary outcomes: the rate and duration of psychiatric readmissions.
RESULTS: We included 98 patients with BD. In ITT analyses, there was no statistically significant difference in rates (hazard rate: 1.05, 95% CI: 0.54; 1.91, p = 0.88) or duration of readmission between the two groups (B: 3.67, 95% CI: -4.77; 12.11, p = 0.39). There was no difference in scores on the Hamilton Depression Rating Scale (B = -0.11, 95% CI: -2.50; 2.29, p = 0.93). The intervention group had higher scores on the Young Mania Rating Scale (B: 1.89, 95% CI: 0.0078; 3.78, p = 0.050). The intervention group reported lower levels of perceived stress (B: -7.18, 95% CI: -13.50; -0.86, p = 0.026) and lower levels of rumination (B: -6.09, 95% CI: -11.19; -1.00, p = 0.019).
CONCLUSIONS: Smartphone-based monitoring did not reduce rate and duration of readmissions. There was no difference in levels of depressive symptoms. The intervention group had higher levels of manic symptoms, but lower perceived stress and rumination compared with the control group.
© 2020 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  RADMIS; bipolar disorder; randomized controlled trial; readmission; smartphone; the Monsenso system

Year:  2021        PMID: 33354769     DOI: 10.1111/acps.13274

Source DB:  PubMed          Journal:  Acta Psychiatr Scand        ISSN: 0001-690X            Impact factor:   6.392


  3 in total

1.  The growing field of digital psychiatry: current evidence and the future of apps, social media, chatbots, and virtual reality.

Authors:  John Torous; Sandra Bucci; Imogen H Bell; Lars V Kessing; Maria Faurholt-Jepsen; Pauline Whelan; Andre F Carvalho; Matcheri Keshavan; Jake Linardon; Joseph Firth
Journal:  World Psychiatry       Date:  2021-10       Impact factor: 49.548

2.  Within Clinic Reliability and Usability of a Voice-Based Amazon Alexa Administration of the Patient Health Questionnaire 9 (PHQ 9).

Authors:  Jason Beaman; Luke Lawson; Ashley Keener; Michael L Mathews
Journal:  J Med Syst       Date:  2022-05-10       Impact factor: 4.920

3.  Phrase of attentiveness: Use of smart phone applications for mental health concerns.

Authors:  Hareem Arshad; Samiullah Dahri; Muhammad Yusuf Hafiz
Journal:  Ann Med Surg (Lond)       Date:  2022-09-25
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.